Psyence Biomedical (PBM) Net Cash Flow (2023)

Psyence Biomedical (PBM) recorded quarterly Net Cash Flow of -$1.6 million in Q1 2023.

Psyence Biomedical (PBM) Net Cash Flow (2023) Analysis & Trends

Psyence Biomedical's Net Cash Flow history runs 1 years deep, the most recent figure standing at -$1.6 million for Q1 2023.

In Q1 2023, Net Cash Flow changed N/A year-over-year to -$1.6 million; the TTM figure through Mar 2025 stood at -$1.6 million (changed N/A YoY), while the FY2024 annual figure was -$3.0 million, down 604.05% from the prior year.
Net Cash Flow was -$1.6 million for Q1 2023 at Psyence Biomedical.
In the past five years, Net Cash Flow ranged from a high of -$1.6 million in Q1 2023 to a low of -$1.6 million in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	2.44 Mn
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	625.70 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-2.44 Mn
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	457.40 Mn
9	Abivax	94.26 Bn	94.26 Bn	-	664,983.53
10	Regeneron Pharmaceuticals	66.09 Bn	57.33 Bn	3.31 Bn	-152.20 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2023	-1.59 Mn
Mar 31, 2023	-1.59 Mn